Dietary Antioxidant Vitamins and Minerals and Breast Cancer Risk: Prospective Results from the SUN Cohort

Cesar I. Fernandez-Lazaro 1,2,*, Miguel Ángel Martinez-González 1,2,3,4, Inmaculada Aguilera-Buenosvinos 1,2,*, Alfredo Gea 1,2,3, Miguel Ruiz-Canela 1,2,3, Andrea Romanos-Nanclares 1,2 and Estefanía Toledo 1,2,3,4

Abstract: There is growing interest in natural antioxidants and their potential effects on breast cancer (BC). Epidemiological evidence, however, is inconsistent. We prospectively evaluated the association between dietary intake of vitamins A, C, and E, selenium, and zinc and BC among 9983 female participants from the SUN Project, a Mediterranean cohort of university graduates. Participants completed a food frequency questionnaire at baseline, and biennial follow-up information about incident BC was collected. Cases were ascertained through revision of medical charts and consultation of the National Death Index. Cox proportional hazards models were used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CI). During an average follow-up of 11.3 years, 107 incident BC cases were confirmed. The multivariable HRs (95% CI) for BC comparing extreme tertiles of energy-adjusted dietary intakes were 1.07 (0.64–1.77; P trend = 0.673) for vitamin A, 1.00 (0.58–1.71; P trend = 0.846) for vitamin C, 0.92 (0.55–1.54; P trend = 0.728) for vitamin E, 1.37 (0.85–2.20; P trend = 0.135) for selenium, and 1.01 (0.61–1.69; P trend = 0.939) for zinc. Stratified analyses showed an inverse association between vitamin E intake and postmenopausal BC (HR T3 vs. T1 = 0.35; 95% CI, 0.14–0.86; P trend = 0.027). Our results did not suggest significant protective associations between dietary vitamins A, C, and E, selenium, or zinc and BC risk.

Keywords: breast cancer; antioxidants; vitamin A; vitamin C; vitamin E; selenium; zinc; SUN cohort; Mediterranean population

1. Introduction

Cancer is currently the most common cause of premature mortality in most developed countries and ranks second in terms of global mortality, accounting for 9.6 million deaths in 2018 [1,2]. Moreover, the incidence of cancer is expected to increase as the population ages [3]. In 2018, cancer was the leading cause of death in Spain for both men and women, with 297.8 and 186.7 deaths per 100,000 inhabitants, respectively [4]. Genetic predisposition is a well-known risk factor but it is estimated that the contribution of genetic factors on cancer risk is approximately between 5% and 10%, whereas environmental and lifestyle factors may account for the remaining 90–95% of cases [5]. Among environmental factors, cumulative lifetime exposure to oxidative damage has been suggested to be involved in both cancer initiation and progression [6]. Diet, a potentially modifiable lifestyle risk factor, may contribute up to 35% of cancer cases, which highlights opportunities for cancer incidence prevention [5].

Extensive and robust evidence has demonstrated in the last few decades that diet plays a direct role in the development of certain types of cancer, such as breast cancer...
In this context, natural compounds in the diet, including vitamins and minerals, have been postulated as anticarcinogenic agents due to their antioxidant properties [10,11]. These micronutrients prevent an excess of reactive oxygen species (ROS) and maintain an adequate reduction–oxidation balance. ROS production promotes DNA damage in cancer and genetic instability. Antioxidants can scavenge free radicals and quench the process of lipid peroxidation, which may reduce the oxidative DNA damage caused by free radicals, and ultimately protect against BC [12,13]. Antioxidant vitamins and minerals interrupt free radical chain reactions and operate in the early and late stages of carcinogenesis. Furthermore, antioxidants promote cancer cell death by producing modifications in cell signaling, changes in the cell cycle progression, and modulation of enzymatic activities [14].

Despite the existing evidence on the anticarcinogenic activity of antioxidants in vitro and animal studies, results from epidemiological studies have engaged extensive controversy owing to inconsistent findings [15–18]. Some studies have reported no clear evidence for the association between dietary antioxidants and BC [15,16,18], whereas few others have suggested possible inverse associations [17,19]. Hence, we aimed to prospectively investigate whether dietary intake of vitamins A, C, and E, selenium, and zinc was associated with risk of overall, pre-, and postmenopausal BC in the SUN (Seguimiento Universidad de Navarra) Study, a Mediterranean cohort of graduates.

2. Materials and Methods

2.1. Study Population

The SUN Project [20] is a large, prospective, ongoing, and permanently open cohort of Spanish university graduates. The design, objectives, and methods of the SUN cohort have been described elsewhere [21]. Briefly, the cohort aims to assess the role of diet and lifestyle on chronic disease prevention and mortality. Participant recruitment started in December 1999, and follow-up information has been biennially assembled using mailed or online questionnaires.

By December 2019, a total of 22,894 participants had completed the baseline questionnaire. For the analysis of the present study, we excluded men (n = 8831) and participants recruited after March 2017 (n = 230). This exclusion was performed to guarantee a follow-up time of at least two years. Among the remaining female participants, we excluded 1225 participants without follow-up (overall retention 91%), 108 women with previous BC history, and 232 participants who reported menopause before the age of 35 years. We additionally excluded 1338 women with daily energy intake out of predefined limits (<500 or >3500 kcal/d) [22] and participants who reported extreme levels (> 3 standard deviations [SD]) of vitamins A, C, and E, selenium, or zinc intake (n = 947). The final sample for the present study analyses consisted of 9983 female participants (Figure 1).

2.2. Exposure Assessment

Dietary intake information was assessed at baseline with a 136-item semi-quantitative food frequency questionnaire (FFQ) previously validated in Spain [23–25]. Validation of the FFQ with repeated 3-day dietary records showed an intra-class correlation coefficient (ICC) = 0.84 for vitamin A, ICC = 0.87 for vitamin C, and ICC = 0.75 for vitamin E [25]. Participants reported their average frequency of food consumption (nine categories ranging from “never” to “more than six times per day”) in common serving size. Food composition tables were used to calculate energy and nutrient intakes for each participant [26,27]. The nutrient contribution of each food item was calculated by multiplying the frequency of food consumption by the nutrient composition of the specified portion size. Nutrients were adjusted for energy intake with the residuals method [22] and categorized into tertiles.
Figure 1. Flowchart of study participants for the assessment of the association of vitamin A, vitamin C, vitamin E, selenium, and zinc and incident intake and breast cancer in the SUN (University of Navarra Follow-up) Project (1999–2020).

2.3. Incident Breast Cancer Ascertainment

The primary endpoint of the current study was incident BC. In the biennial follow-up questionnaires, women were asked to self-report any new diagnosis of BC, and medical records were requested in order to confirm the diagnosis. A trained oncologist, blinded to the different exposures, reviewed participants’ medical records, and confirmed the diagnosis. Information on fatal causes was reported to our research team by the subjects’ next of kin, postal authorities, or work associates. Furthermore, we consulted the National Death Index at least once a year to identify deceased cohort members when participants were lost to follow-up, or when we had no information on the death causes. Women for
whom the reported cause of death in the National Death Index was BC were treated as confirmed incident cases.

2.4. Covariates

At baseline, participants provided information regarding socio-demographic characteristics, anthropometric measures, lifestyle behaviors (i.e., smoking, alcohol intake, physical activity, among others), medical history, and obstetric information (i.e., family history of BC, number of and age at pregnancies, months of breastfeeding, age of menarche, menopausal status, and age at menopause if applicable). Accuracy of self-reported weight and height to calculate body mass index (BMI) was previously validated in a subsample of this cohort [28]. Physical activity information was gathered with a previously validated questionnaire [29]. We estimated metabolic equivalents (METs) for each participant to obtain METs-h/week dedicated to all physical activities performed during leisure time. Adherence to the Mediterranean Diet (MedDiet) was assessed with the score proposed by Trichopoulou et al. [30], excluding alcohol intake. Hence, the MedDiet score ranged from 0 to 8, with higher scores meaning greater adherence.

2.5. Statistical Analysis

Descriptive statistics were used to summarize the characteristics of the study population at baseline. The contribution of each food included in the FFQ to the between-subject variation of dietary exposures intake was estimated by nested regression analyses after a stepwise regression and expressed as cumulative $R^2$ change. We additionally calculated the percentage (%) of the contribution of each FFQ item and food groups to the dietary exposure intakes.

Cox proportional hazard models were performed to examine the association of energy-adjusted tertiles of vitamins A, C, and E, selenium, and zinc intake with BC risk. Results were expressed as hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs), considering the lowest tertile as the reference category. All models included age as an underlying time variable and were additionally stratified by year of recruitment (four categories) and age at recruitment (decades). Time at entry was the date of completion of the baseline questionnaire; exit time was the age when participants were diagnosed with BC, died, or responded the latest follow-up questionnaire, if they were alive and free of BC at the end of follow-up. After crude analyses, different models were fitted to include potential confounders that may influence the effects of the study exposures on BC risk; model 1 was adjusted for age at menarche (four categories), age at menopause (three categories), alcohol intake (g/d, continuous), breastfeeding (months, continuous), BMI (kg/m², continuous), height (cm, continuous), hormone replacement therapy (dichotomous) and its duration (years, continuous), obstetric history (five categories), physical activity (METs-h/week, continuous), relatives with history of BC (three categories), smoking habit (package/year, continuous), smoking status (three categories), and years at university (continuous); model 2 was additionally adjusted for calcium intake (mg/d, continuous), coffee consumption (two categories), fat intake (E%, continuous), Mediterranean diet adherence (points, continuous), sugar-sweetened beverage consumption (three categories), total energy intake (Kcal/d, continuous), TV-watching (hours/d, continuous), and use of supplements (dichotomous). The confounders of the study were selected considering previously published literature and preceding results of the SUN cohort on BC [31–34]. We performed tests of linear trend across tertiles of vitamins A, C, and E, selenium, and zinc intake by assigning the median value to each tertile and treating the resulting variables as continuous.

We stratified our analyses by menopausal BC. Information regarding menopause was collected at baseline and after 16 years of follow-up. When this information was not available, age at menopause was considered to be 52 years (percentile 75 of those women who reported age at menopause) [35]. For premenopausal BC as outcome, only women without menopause at baseline were considered, and follow-up time was censored at the age when participants self-reported menopause or at the age of 52 years, whichever
happened first. For postmenopausal BC as outcome, we examined women with menopause at baseline or premenopausal women only after their self-reported menopause during the follow-up or after they had turned 52 years during the follow-up, whichever happened last. For premenopausal analyses, models were not adjusted for age at menopause, use of hormone replacement therapy and its duration. For postmenopausal analyses, models were additionally adjusted for time since recruitment until the beginning of the time at risk (years, continuous).

We additionally repeated our analyses considering only luminal BC. As information related to cancer subtype was not available for all the BC incident cases and the number of some BC subtypes was relatively low, we limited our analyses to confirmed luminal BC.

To assess the robustness of our findings, we performed sensitivity by re-running our models after excluding participants with a follow-up of <2 years, truncating the participants’ follow-up at 10 years, and using an alternative definition of exposure. The exposure was defined as total intake of sources from both diet and supplements, except for selenium supplemental intake which information was not available. For regular multivitamin and supplement users, information regarding dosage, brand, and frequency was collected.

All analyses were performed using Stata software, version 16.0 (Stata Corporation LP, College Station, TX, USA), and a 2-sided $p$-value < 0.05 was deemed as statistically significant. Missing covariate data were imputed with regression equations to predict missing values. Imputations did not imply any missing outcome and represented < 5% of missing covariates.

3. Results

During a mean average of 11.3 years of follow-up, 107 incident BC cases were diagnosed in 9983 women. The crude BC incidence was 94.7 per 100,000 person-year. Among the 72 cases with known subtype, 57 cases were luminal (79.2%), 8 cases were HER2 (11.1%), and 7 cases were triple negative (9.7%) tumors. The distribution of the study subjects by baseline characteristics is summarized in Table 1. The mean age of participants was 35.1 years (SD = 10.5 years), most of them were non-smokers, non-users of multivitamin or mineral supplements, had a low consumption of sugar-sweetened beverages, and they were largely nulliparous and mostly premenopausal.

Pearson correlations between dietary intake of antioxidants (non-energy-adjusted) and energy intake were moderate for selenium ($r = 0.58$), vitamin E ($r = 0.57$), and weaker for zinc ($r = 0.36$), vitamin C ($r = 0.36$), and vitamin A ($r = 0.29$). The individual and cumulative contributions of different foods to the variability in antioxidant vitamins and minerals as well as the between-person variability are shown in Supplemental Table S1. In brief, the primary food group contributors of dietary daily intake were vegetables and fruits for vitamins A and C, fats and oils for vitamin E, fish and seafood for selenium, and dairy products for zinc. Regarding sources of variability, fruits and vegetables explained more than 98% of the between-person variability for vitamin A and C intake, while fats and oils explained 43% for vitamin E intake, cereals and legumes 40% of selenium intake, and dairy products represented 82% of the between-person variability for zinc intake.

Hazard ratios and 95% CI for the risk of BC according to dietary intake of vitamin A, vitamin C, and vitamin E among overall, premenopausal, and postmenopausal women are shown in Tables 2–4, respectively. Dietary vitamin A, vitamin C, and vitamin E intakes were not significantly associated with overall BC risk (highest vs. lowest tertile): HR, 1.07; 95%CI (0.64–1.77; $P_{\text{trend}} = 0.673$) for vitamin A; 1.00 (0.58–1.71; $P_{\text{trend}} = 0.846$) for vitamin C; and 0.92 (0.55–1.54; $P_{\text{trend}} = 0.728$) for vitamin E. When we stratified by menopausal status, no significant association was observed between tertiles of these antioxidant dietary intakes and BC incidence, except for vitamin E intake. Among postmenopausal women, we found an inverse association between vitamin E intake and BC risk for tertile 3 vs. tertile 1: HR, 0.35; 95% CI (0.14–0.86; $P_{\text{trend}} = 0.027$).
Table 1. Baseline characteristics of the female study participants of the Seguimiento Universidad de Navarra (SUN) Project (n = 9983).

| Characteristics                              | Total Cohort |
|----------------------------------------------|--------------|
| N (frequency)                                | 9983         |
| Age, years                                   | 35.1 (10.5)  |
| Height, cm                                   | 163.6 (6.0)  |
| BMI, kg/m²                                    | 22.2 (3.0)   |
| Marital status, married, n(%)                | 4287 (42.9%) |
| Years of university studies                  | 4.8 (1.3)    |
| Smoking status at baseline, n(%)             |              |
| Never smokers                                | 5153 (51.6%) |
| Current smokers                              | 2304 (23.1%) |
| Former smokers                               | 2526 (25.3%) |
| Cumulative smoking habit, packs-years         | 3.4 (7.0)    |
| Alcohol intake, g/d                          | 4.1 (5.9)    |
| Coffee consumption, >1 cup/d                 | 4601 (46.1%) |
| Physical activity at baseline, METs-h/week    | 18.4 (19.1)  |
| TV-watching, h/d                             | 1.6 (1.2)    |
| Oral contraceptive use, n(%)                | 237 (2.4%)   |
| Multivitamin and/or mineral users at baseline, n(%) | 2229 (22.3%) |
| Self-reported diabetes at baseline, n(%)     | 102 (1.0%)   |

Diet, energy, and nutrients

| Adherence to the Mediterranean diet a       | 3.8 (1.7)    |
| Sugar-sweetened beverage consumption, n(%)  |              |

1/month to ≤1 serving/week, >1 servings/week

Total energy intake, kcal/d                   | 2279 (571)   |
Carbohydrate intake, % E                      | 43.2 (7.2)   |
Protein intake, % E                            | 18.3 (3.2)   |
Fat intake, % E                                | 37.2 (6.4)   |
Saturated fatty acids, % E                     | 12.6 (3.1)   |
Monounsaturated fatty acids, % E              | 16.1 (3.8)   |
Polyunsaturated fatty acids, % E              | 5.1 (1.4)    |

Family history of breast cancer (first degree), n(%) | 1063 (10.6%) |

Reproductive history

Obstetric history

Nulliparous & <25 years                        | 1789 (17.9%) |
Nulliparous & ≥25 years                        | 4881 (48.9%) |
First pregnancy before 25 years                | 450 (4.5%)   |
First pregnancy between 25–29 years            | 1461 (14.6%) |
First pregnancy being 30 years or older        | 1402 (14.0%) |
Lifetime breastfeeding, months                 | 2.3 (4.9)    |
Age of menarche, n (%)                         |              |
≤11 years                                      | 2001 (20.0%) |
12–13 years                                    | 5474 (54.8%) |
13–14 years                                    | 1703 (17.1%) |
>15 years                                      | 805 (8.1%)   |
Menopausal status at baseline, n (%)           |              |
Premenopausal                                   | 9239 (92.5%) |
Postmenopausal                                  | 744 (7.5%)   |
Age at menopause, n (%) b                      |              |
Postmenopausal < 50 years                      | 318 (42.7%)  |
Postmenopausal ≥ 50 years                      | 426 (57.3%)  |
Cause of menopause, n (%) b                    |              |
Natural                                        | 643 (86.4%)  |
Induced                                        | 101 (13.6%)  |
Hormone replacement therapy, n (%) b           |              |
Ever-use                                       | 446 (4.5%)   |
Duration of use, years                         | 1.4 (2.5)    |

Note: Mean values and standard deviations, unless otherwise stated. Abbreviations: BMI, body mass index; E, energy; MET, metabolic equivalent. a Modified Mediterranean adherence score proposed by Trichopoulou et al. [32]. b Among postmenopausal women. c Induced menopause included menopause due to surgery/hysterectomy, radiation, medication, or other conditions.
### Table 2. Dietary vitamin A intake. Hazard Ratio (HR) and 95% Confidence Interval (CI) of breast cancer by tertiles of energy-adjusted dietary vitamin A at baseline among female participants of the SUN cohort.

| Tertiles of Energy-Adjusted Dietary Vitamin A Intake | T1 | T2 | T3 | P for Trend |
|----------------------------------------------------|----|----|----|-------------|
| **Overall**                                         |    |    |    |             |
| Intake range, (mcg/d)                               | <1387 | 1387–2282 | >2282 |             |
| Median intake, (mcg/d)                              | 1033 | 1747 | 2984 |             |
| No of participants                                 | 3328 | 3328 | 3327 |             |
| Person-years                                       | 38,540 | 37,718 | 36,740 |             |
| Cases                                              | 36 | 31 | 40 |             |
| Incidence rate/10,000 person-years                 | 9.34 | 821 | 10.88 |             |
| Age-adjusted                                       | 1.00 (reference) | 0.80 (0.49–1.29) | 0.96 (0.61–1.50) | 0.998 |
| Model 1                                            | 1.00 (reference) | 0.77 (0.48–1.26) | 0.94 (0.59–1.50) | 0.975 |
| Model 2                                            | 1.00 (reference) | 0.85 (0.51–1.41) | 1.07 (0.64–1.77) | 0.673 |
| **Premenopausal**                                   |    |    |    |             |
| Intake range, (mcg/d)                               | <1366 | 1366–2250 | >2250 |             |
| Median intake, (mcg/d)                              | 1017 | 1719 | 2944 |             |
| No of participants                                 | 3077 | 3077 | 3076 |             |
| Person-years                                       | 33,149 | 32,113 | 30,580 |             |
| Cases                                              | 22 | 20 | 18 |             |
| Incidence rate/10,000 person-years                 | 6.64 | 6.23 | 5.89 |             |
| Age-adjusted                                       | 1.00 (reference) | 0.88 (0.48–1.61) | 0.78 (0.42–1.45) | 0.434 |
| Model 1                                            | 1.00 (reference) | 0.88 (0.48–1.63) | 0.77 (0.40–1.46) | 0.423 |
| Model 2                                            | 1.00 (reference) | 0.95 (0.50–1.80) | 0.81 (0.40–1.62) | 0.537 |
| **Postmenopausal**                                  |    |    |    |             |
| Intake range, (mcg/d)                               | <1513 | 1513–2499 | >2499 |             |
| Median intake, (mcg/d)                              | 1153 | 1924 | 3249 |             |
| No of participants                                 | 987 | 987 | 987 |             |
| Person-years                                       | 6307 | 6860 | 6844 |             |
| Cases                                              | 12 | 10 | 17 |             |
| Incidence rate/10,000 person-years                 | 19.02 | 14.58 | 24.84 |             |
| Age-adjusted                                       | 1.00 (reference) | 0.80 (0.35–1.86) | 1.35 (0.65–2.84) | 0.311 |
| Model 1                                            | 1.00 (reference) | 0.72 (0.31–1.70) | 1.51 (0.70–3.23) | 0.178 |
| Model 2                                            | 1.00 (reference) | 0.78 (0.32–1.90) | 1.72 (0.73–4.01) | 0.127 |

Abbreviations: CI, confidence interval; HR, hazard ratio; Ref., reference. -Model 1: crude model additionally adjusted for age of menarche (four categories), age at menopause (three categories), alcohol intake (g/d, continuous), breastfeeding (months, continuous), BMI (kg/m$^2$, continuous), height (cm, continuous), hormone replacement therapy (dichotomous) and its duration (years, continuous), obstetric history (five categories), physical activity (metabolic equivalent-h/week, continuous), relatives with history of breast cancer (three categories), smoking habit (package/year, continuous), smoking status (three categories), and years at university (continuous). For premenopausal women, models were not adjusted for age at menopause, hormone replacement therapy, and its duration. For postmenopausal women, models were additionally adjusted for time since recruitment until the beginning of the time at risk (years, continuous). -Model 2: model 1 additionally adjusted for calcium intake (mg/d, continuous), coffee consumption (two categories), fat intake (E%, continuous), Mediterranean diet adherence (points, continuous), sugar-sweetened beverages (three categories), total energy intake (Kcal/d, continuous), TV-watching (hours/d, continuous), and use of supplements (dichotomous).
Table 3. Dietary vitamin C intake. Hazard Ratio (HR) and 95% Confidence Interval (CI) of breast cancer by tertiles of energy-adjusted dietary vitamin C at baseline among female participants of the SUN cohort.

| Tertiles of Energy-Adjusted of Dietary Vitamin C Intake | Overall | T1 | T2 | T3 | P for Trend |
|--------------------------------------------------------|---------|----|----|----|-------------|
| Intake range, (mg/d)                                   | <219   | 219–322 | >322 | | |
| Median intake, (mg/d)                                  | 168    | 265  | 406 | | |
| No of participants                                    | 3328   | 3328 | 3327 | | |
| Person-years                                         | 38,458 | 37,754 | 36,878 | | |
| Cases                                                | 39     | 28    | 40   | | |
| Incidence rate/10,000 person-years                    | 10.14  | 7.41  | 10.87 | | |
| Age-adjusted                                         | 1.00 (reference) | 0.68 (0.42–1.10) | 0.89 (0.57–1.39) | 0.756 | |
| Model 1                                               | 1.00 (reference) | 0.70 (0.43–1.15) | 0.92 (0.58–1.46) | 0.866 | |
| Model 2                                               | 1.00 (reference) | 0.73 (0.43–1.22) | 1.00 (0.58–1.71) | 0.846 | |
| Premenopausal                                         | | | | | |
| Intake range, (mg/d)                                  | <216   | 216–317 | >317 | | |
| Median intake, (mg/d)                                  | 167    | 262  | 401 | | |
| No of participants                                    | 3077   | 3077 | 3076 | | |
| Person-years                                         | 33,385 | 31,971 | 30,485 | | |
| Cases                                                | 23     | 18    | 19   | | |
| Incidence rate/10,000 person-years                    | 6.89   | 5.63  | 6.23 | | |
| Age-adjusted                                         | 1.00 (reference) | 0.73 (0.44–1.22) | 0.82 (0.50–1.33) | 0.485 | |
| Model 1                                               | 1.00 (reference) | 0.76 (0.46–1.28) | 0.87 (0.53–1.44) | 0.652 | |
| Model 2                                               | 1.00 (reference) | 0.76 (0.44–1.31) | 0.88 (0.49–1.59) | 0.758 | |
| Postmenopausal                                        | | | | | |
| Intake range, (mg/d)                                  | <235   | 235–348 | >348 | | |
| Median intake, (mg/d)                                  | 181    | 289  | 432 | | |
| No of participants                                    | 987    | 987  | 987 | | |
| Person-years                                         | 6016   | 6914 | 7081 | | |
| Cases                                                | 11     | 12    | 16   | | |
| Incidence rate/10,000 person-years                    | 18.29  | 17.36 | 22.60 | | |
| Age-adjusted                                         | 1.00 (reference) | 0.98 (0.43–2.23) | 1.28 (0.59–2.77) | 0.485 | |
| Model 1                                               | 1.00 (reference) | 1.00 (0.43–2.31) | 1.40 (0.63–3.12) | 0.368 | |
| Model 2                                               | 1.00 (reference) | 1.13 (0.46–2.74) | 1.72 (0.66–4.45) | 0.234 | |

Abbreviations: CI, confidence interval; HR, hazard ratio; Ref., reference. -Model 1: crude model additionally adjusted for age of menarche (four categories), age at menopause (three categories), alcohol intake (g/d, continuous), breastfeeding (months, continuous), BMI (kg/m², continuous), height (cm, continuous), hormone replacement therapy (dichotomous) and its duration (years, continuous), obstetric history (five categories), physical activity (metabolic equivalent-h/week, continuous), relatives with history of breast cancer (three categories), smoking habit (package/year, continuous), smoking status (three categories), and years at university (continuous). For premenopausal women, models were not adjusted for age at menopause, hormone replacement therapy and its duration. For menopausal women, models were additionally adjusted for time since recruitment until the beginning of the time at risk (years, continuous). -Model 2: model 1 additionally adjusted for calcium intake (mg/d, continuous), coffee consumption (two categories), fat intake (E%, continuous), Mediterranean diet adherence (points, continuous), sugar-sweetened beverages (three categories), total energy intake (Kcal/d, continuous), TV-watching (hours/d, continuous), and use of supplements (dichotomous).
Table 4. Dietary vitamin E intake. Hazard Ratio (HR) and 95% Confidence Interval (CI) of breast cancer by tertiles of energy-adjusted dietary vitamin E at baseline among female participants of the SUN cohort.

| Tertiles of Energy-Adjusted of Dietary Vitamin E Intake | T1     | T2     | T3     | *P* for Trend |
|-------------------------------------------------------|--------|--------|--------|--------------|
| **Overall**                                           |        |        |        |              |
| Intake range, (mg/d)                                  | <5.56  | 5.56–7.15 | >7.15  |              |
| Median intake, (mg/d)                                 | 4.68   | 6.30   | 8.87   |              |
| No of participants                                    | 3328   | 3328   | 3327   |              |
| Person-years                                          | 38,036 | 37,475 | 37,478 |              |
| Cases                                                 | 38     | 36     | 33     |              |
| Incidence rate/10,000 person-years                    | 9.99   | 9.61   | 8.80   |              |
| Age-adjusted                                          | 1.00 (reference) | 0.94 (0.60–1.48) | 0.86 (0.54–1.37) | 0.525          |
| Model 1                                               | 1.00 (reference) | 0.94 (0.59–1.48) | 0.86 (0.54–1.38) | 0.533          |
| Model 2                                               | 1.00 (reference) | 1.00 (0.62–1.63) | 0.92 (0.55–1.54) | 0.728          |
| **Premenopausal**                                     |        |        |        |              |
| Intake range, (mg/d)                                  | <5.53  | 5.53–7.13 | >7.13  |              |
| Median intake, (mg/d)                                 | 4.66   | 6.27   | 8.79   |              |
| No of participants                                    | 3077   | 3077   | 3076   |              |
| Person-years                                          | 32,260 | 31,894 | 31,687 |              |
| Cases                                                 | 17     | 26     | 17     |              |
| Incidence rate/10,000 person-years                    | 5.27   | 8.15   | 5.37   |              |
| Age-adjusted                                          | 1.00 (reference) | 1.00 (0.61–1.64) | 0.93 (0.56–1.55) | 0.779          |
| Model 1                                               | 1.00 (reference) | 0.99 (0.60–1.62) | 0.95 (0.57–1.58) | 0.832          |
| Model 2                                               | 1.00 (reference) | 1.05 (0.62–1.79) | 1.03 (0.59–1.81) | 0.924          |
| **Postmenopausal**                                    |        |        |        |              |
| Intake range, (mg/d)                                  | <5.63  | 5.63–7.27 | >7.27  |              |
| Median intake, (mg/d)                                 | 4.74   | 6.41   | 9.10   |              |
| No of participants                                    | 987    | 987    | 987    |              |
| Person-years                                          | 6592   | 6568   | 6850   |              |
| Cases                                                 | 20     | 10     | 9      |              |
| Incidence rate/10,000 person-years                    | 30.33  | 15.22  | 13.14  |              |
| Age-adjusted                                          | 1.00 (reference) | 0.50 (0.24–1.08) | 0.44 (0.20–0.96) | 0.042          |
| Model 1                                               | 1.00 (reference) | 0.47 (0.22–1.01) | 0.40 (0.18–0.90) | 0.028          |
| Model 2                                               | 1.00 (reference) | 0.45 (0.20–1.04) | 0.35 (0.14–0.86) | 0.027          |

Abbreviations: CI, confidence interval; HR, hazard ratio; Ref., reference. -Model 1: crude model additionally adjusted for age of menarche (four categories), age at menopause (three categories), alcohol intake (g/d, continuous), breastfeeding (months, continuous), BMI (kg/m², continuous), height (cm, continuous), hormone replacement therapy (dichotomous) and its duration (years, continuous), obstetric history (five categories), physical activity (metabolic equivalent-h/week, continuous), relatives with history of breast cancer (three categories), smoking habit (package/year, continuous), smoking status (three categories), and years at university (continuous). For premenopausal women, models were not adjusted for age at menopause, hormone replacement therapy and its duration. For menopausal women, models were additionally adjusted for time since recruitment until the beginning of the time at risk (years, continuous). -Model 2: model 1 additionally adjusted for calcium intake (mg/d, continuous), coffee consumption (two categories), fat intake (E%, continuous), Mediterranean diet adherence (points, continuous), sugar-sweetened beverages (three categories), total energy intake (Kcal/d, continuous), TV-watching (hours/d, continuous), and use of supplements (dichotomous).

Tables 5 and 6 show the results for multivariable-adjusted models assessing dietary intakes of selenium and zinc with overall BC and among pre- and postmenopausal women. No significant association was observed between antioxidant minerals intake and overall BC, either for premenopausal or postmenopausal BC, across different levels of dietary antioxidant intake.
Table 5. Dietary selenium intake. Hazard Ratio (HR) and 95% Confidence Interval (CI) of breast cancer by tertiles of energy-adjusted dietary selenium at baseline among female participants of the SUN cohort.

| Tertiles of Energy-Adjusted of Dietary Selenium Intake | T1 | T2 | T3 | P for Trend |
|-------------------------------------------------------|----|----|----|-------------|
| **Overall**                                           |    |    |    |             |
| Intake range, (mcg/d)                                  | <80.9 | 80.9–101.1 | >101.1 |             |
| Median intake, (mcg/d)                                 | 69.0 | 90.5 | 114.5 |             |
| No of participants                                    | 3328 | 3328 | 3327 |             |
| Person-years                                          | 37,884 | 37,563 | 37,553 |             |
| Cases                                                 | 32 | 26 | 49 |             |
| Incidence rate/10,000 person-years                    | 8.44 | 6.92 | 13.05 |             |
| Age-adjusted                                          | 1.00 (reference) | 0.74 (0.44–1.25) | 1.26 (0.81–1.97) | 0.215 |
| Model 1                                               | 1.00 (reference) | 0.73 (0.43–1.23) | 1.27 (0.81–1.99) | 0.209 |
| Model 2                                               | 1.00 (reference) | 0.76 (0.45–1.29) | 1.37 (0.85–2.20) | 0.135 |
| **Premenopausal**                                     |    |    |    |             |
| Intake range, (mcg/d)                                  | <80.4 | 80.4–100.3 | >100.3 |             |
| Median intake, (mcg/d)                                 | 68.6 | 90.1 | 113.8 |             |
| No of participants                                    | 3077 | 3077 | 3076 |             |
| Person-years                                          | 32,766 | 31,929 | 31,147 |             |
| Cases                                                 | 19 | 17 | 24 |             |
| Incidence rate/10,000 person-years                    | 5.80 | 5.32 | 7.71 |             |
| Age-adjusted                                          | 1.00 (reference) | 0.67 (0.38–1.17) | 1.18 (0.73–1.90) | 0.379 |
| Model 1                                               | 1.00 (reference) | 0.64 (0.36–1.13) | 1.24 (0.77–2.01) | 0.268 |
| Model 2                                               | 1.00 (reference) | 0.65 (0.37–1.16) | 1.29 (0.78–2.14) | 0.226 |
| **Postmenopausal**                                    |    |    |    |             |
| Intake range, (mcg/d)                                  | < 84.5 | 84.5–105.2 | > 105.2 |            |
| Median intake, (mcg/d)                                 | 72.7 | 93.8 | 118.2 |             |
| No of participants                                    | 987 | 987 | 987 |             |
| Person-years                                          | 6360 | 6663 | 6988 |             |
| Cases                                                 | 11 | 8 | 20 |             |
| Incidence rate/10,000 person-years                    | 17.30 | 12.01 | 28.62 |             |
| Age-adjusted                                          | 1.00 (reference) | 0.69 (0.28–1.71) | 1.68 (0.80–3.51) | 0.106 |
| Model 1                                               | 1.00 (reference) | 0.64 (0.25–1.61) | 1.65 (0.78–3.48) | 0.115 |
| Model 2                                               | 1.00 (reference) | 0.68 (0.27–1.75) | 1.70 (0.77–3.75) | 0.118 |

Abbreviations: CI, confidence interval; HR, hazard ratio; Ref., reference. -Model 1: crude model additionally adjusted for age of menarche (four categories), age at menopause (three categories), alcohol intake (g/d, continuous), breastfeeding (months, continuous), BMI (kg/m², continuous), height (cm, continuous), hormone replacement therapy (dichotomous) and its duration (years, continuous), obstetric history (five categories), physical activity (metabolic equivalent-h/week, continuous), relatives with history of breast cancer (three categories), smoking habit (package/year, continuous), smoking status (three categories), and years at university (continuous). For premenopausal women, models were not adjusted for age at menopause, hormone replacement therapy and its duration. For menopausal women, models were additionally adjusted for time since recruitment until the beginning of the time at risk (years, continuous). -Model 2: model 1 additionally adjusted for calcium intake (mg/d, continuous), coffee consumption (two categories), fat intake (E%, continuous), Mediterranean diet adherence (points, continuous), sugar-sweetened beverages (three categories), total energy intake (Kcal/d, continuous), TV-watching (hours/d, continuous), and use of supplements (dichotomous).
Table 6. Dietary zinc intake. Hazard Ratio (HR) and 95% Confidence Interval (CI) of breast cancer by tertiles of energy-adjusted dietary zinc at baseline among female participants of the SUN cohort.

|                         | Tertiles of Energy-Adjusted of Dietary Zinc Intake |          |          |          |
|-------------------------|---------------------------------------------------|----------|----------|----------|
|                         | Overall                                           | T1       | T2       | T3       | P for Trend |
| Intake range, (mg/d)    | <12.8                                            | 12.8–17.2| >17.2    |          |            |
| Median intake, (mg/d)   | 11.5                                             | 14.2     | 22.9     |          |            |
| No of participants      | 3328                                             | 3328     | 3327     |          |            |
| Person-years            | 39,115                                           | 37,831   | 36,053   |          |            |
| Cases                   | 38                                               | 35       | 34       |          |            |
| Incidence rate/10,000 person-years | 9.72                                           | 9.25     | 9.43     |          |            |
| Age-adjusted HR (Ref.) | 1.00 (reference)                                 | 0.92 (0.58–1.45) | 0.92 (0.58–1.46) | 0.770 |
| Model 1                 | 1.00 (reference)                                 | 0.93 (0.59–1.48) | 0.93 (0.58–1.50) | 0.815 |
| Model 2                 | 1.00 (reference)                                 | 0.98 (0.61–1.58) | 1.01 (0.61–1.69) | 0.939 |

|                         | Premenopausal                                     |          |          |          |
| Intake range, (mg/d)    | <12.8                                            | 12.8–17.0| >17.0    |          |            |
| Median intake, (mg/d)   | 11.5                                             | 14.1     | 22.6     |          |            |
| No of participants      | 3077                                             | 3077     | 3076     |          |            |
| Person-years            | 33,391                                           | 31,851   | 30,600   |          |            |
| Cases                   | 19                                               | 21       | 20       |          |            |
| Incidence rate/10,000 person-years | 5.69                                           | 6.59     | 6.54     |          |            |
| Age-adjusted HR (Ref.) | 1.00 (reference)                                 | 0.95 (0.57–1.57) | 1.06 (0.65–1.75) | 0.729 |
| Model 1                 | 1.00 (reference)                                 | 0.99 (0.59–1.65) | 1.16 (0.69–1.93) | 0.521 |
| Model 2                 | 1.00 (reference)                                 | 1.04 (0.62–1.76) | 1.26 (0.73–2.19) | 0.367 |

|                         | Postmenopausal                                    |          |          |          |
| Intake range, (mg/d)    | <12.9                                            | 12.9–17.6| >17.6    |          |            |
| Median intake, (mg/d)   | 11.6                                             | 14.3     | 24.7     |          |            |
| No of participants      | 987                                              | 987      | 987      |          |            |
| Person-years            | 6406                                             | 6618     | 6987     |          |            |
| Cases                   | 14                                               | 12       | 13       |          |            |
| Incidence rate/10,000 person-years | 21.85                                          | 18.13    | 18.61    |          |            |
| Age-adjusted HR (Ref.) | 1.00 (reference)                                 | 0.84 (0.39–1.83) | 0.85 (0.40–1.82) | 0.761 |
| Model 1                 | 1.00 (reference)                                 | 0.84 (0.39–1.84) | 0.82 (0.37–1.78) | 0.680 |
| Model 2                 | 1.00 (reference)                                 | 0.89 (0.40–1.99) | 0.89 (0.38–2.07) | 0.840 |

Abbreviations: CI, confidence interval; HR, hazard ratio; Ref., reference. -Model 1: crude model additionally adjusted for age of menarche (four categories), age at menopause (three categories), alcohol intake (g/d, continuous), breastfeeding (months, continuous), BMI (kg/m², continuous), height (cm, continuous), hormone replacement therapy (dichotomous) and its duration (years, continuous), obstetric history (five categories), physical activity (metabolic equivalent-h/week, continuous), relatives with history of breast cancer (three categories), smoking habit (package/year, continuous), smoking status (three categories), and years at university (continuous). For premenopausal women, models were not adjusted for age at menopause, hormone replacement therapy and its duration. For menopausal women, models were additionally adjusted for time since recruitment until the beginning of the time at risk (years, continuous). -Model 2: model 1 additionally adjusted for calcium intake (mg/d, continuous), coffee consumption (two categories), fat intake (%E, continuous), Mediterranean diet adherence (points, continuous), sugar-sweetened beverages (three categories), total energy intake (Kcal/d, continuous), TV-watching (hours/d, continuous), and use of supplements (dichotomous).

When we considered luminal BC as outcome, we did not find associations between levels of antioxidant vitamin or mineral intake and BC risk (Supplemental Table S2).

After re-running the models under different assumptions, no evidence of a clear association was found between antioxidants and BC risk. (Supplemental Tables S3–S5).

4. Discussion

In this prospective cohort study of Spanish university graduates, we aimed to prospectively investigate the relationship between the intake of vitamins A, C, and E, selenium, and zinc and BC risk. After multiple adjustments for traditional risk factors, we did not find any evidence of the association between antioxidant vitamins or minerals with overall
BC risk. When we stratified our analyses by menopausal status, an inverse association with BC was observed only for vitamin E intake among postmenopausal women.

A large number of epidemiologic studies have examined for a long period the association of natural antioxidants with BC risk. Findings, however, have been predominantly discordant [15]. Discrepancies in results seem to differ by study design. On the one hand several case-control studies have suggested an inverse relationship between antioxidant vitamins and BC risk. On the other hand, most cohort studies published in the last decade have found no consistent evidence of such association. For example, a recent meta-analysis of observational studies which included the most up-to-date studies on vitamin C intake and BC risk [19] concluded that higher dietary vitamin C intake was significantly associated with a lower BC risk in pooled analyses and case-control studies; nevertheless, no significant observation was observed in subgroup analyses of cohort studies. Similar findings were observed in a previous meta-analysis in which dietary intake of retinol, vitamins A, C, and E became non-significant when data from cohort studies were pooled [16].

Recall and selection bias in case-control studies might explain such inconsistencies between study designs, although no clear explanations exist [36]. Case-control studies are prone to selection bias, particularly diet and cancer studies, due to the difficulty of selecting the appropriate control group [37]. Moreover, recall bias may often occur because cases may associate unhealthy foods and habits with their BC malignancy [15].

The present study provides no evidence of an association between antioxidant vitamins and BC, except for vitamin E and postmenopausal women, but the association was restricted to dietary intake. Evidence of supplementation of antioxidant vitamins has not been compelling for BC [38,39], consistent with prior findings from large cohorts. In the European Prospective Investigation into Cancer and Nutrition (EPIC) study, neither dietary vitamin C nor vitamin E was associated with overall BC, and neither were they in analyses stratified by menopausal status [40]. Similarly, a pooled analysis from five established cohorts in the UK Dietary Cohort Consortium study found no evidence of an association between dietary vitamin C intake and BC risk [17]; these findings are consistent with the Swedish Mammography Screening Cohort in which no overall association between intake of vitamin C, beta-carotene, retinol, or vitamin E and BC incidence was found [41]. Only a few observational studies have assessed the relationship between BC risk and dietary selenium and zinc intake, finding no evidence of such association [42,43]. Interestingly, the conclusions from the systematic review and meta-analysis of prospective studies conducted by Kuria et al. [18] suggested a protective effect of a recommended daily allowance of selenium intake for overall cancer; nevertheless, the potential protective effect was non-significant for BC.

Regarding dietary vitamins and minerals intake, the national recommended dietary allowances intakes for adult women are 600 mcg/d for vitamin A, 60 mg/d for vitamin C, 12 mg/d for vitamin E, 55 mcg/d for selenium, and 7 mg/d for zinc [44]. In our study, median intake in all energy-adjusted antioxidant tertiles was higher than the national recommended dietary allowances, except for vitamin E, for which not even the median intake in the highest tertile met such allowances. The dietary intake levels of vitamin and antioxidants of the present study are higher than the levels reported by the Anibes study, the latest national published research [45].

Animal studies have demonstrated the important role of ROS and breast malignancy [46]. Non-enzymatic antioxidants include natural compounds such as vitamins A, C, and E, or minerals such as selenium and zinc, supplied through foods and supplements that help endogenous compounds reduce a variety of ROS. A potential mechanism for inducing tumor reduction is based on the antioxidants’ capacity to control the redox balance in malignant cells [46,47]. Reactive species may cause severe oxidative stress and may lead to DNA damage, suppress tumor genes, and alter cellular homeostasis leading to carcinogenesis [12,13]. Specifically, vitamin A, selenium, and zinc have been hypothesized to diminish the risk of BC by inhibition of cell proliferation, induction of differentiation, and apoptosis [48–50]. Vitamin C plays a key role as a prooxidant breakage of cellular DNA [51],
and vitamin E additionally suppresses lipid peroxidation and induces apoptosis of tumor cells [52,53]. A major interest has been drawn among postmenopausal women, of whom the consumption of antioxidants has been theorized to have greater benefits than among premenopausal women [54]. While premenopausal women maintain an oxidative balance between ROS and the body’s antioxidant mechanisms, produced mostly by the inhibition of the 8-hydroxylation of guanine DNA bases [55], the levels of estrogens generally decline as menopause nears, leading to increased levels of oxidative stress [56]. Lower levels of estrogens have pro-oxidant effects that may trigger the oxidation of bases, DNA adducts, and genetic material damage [55].

In our study, there was no clear evidence of an association between antioxidants and BC risk. A potential explanation for these results may rely on the bioavailability of antioxidant compounds. Some authors have suggested that not only intake levels but also their bioavailability may influence their health benefits [57]. Furthermore, compounds’ antioxidant activity largely depends on the cooking method, as foods may suffer losses of antioxidant properties [58]. Environmental and cultivation conditions may also play a significant role on the antioxidant activity of certain foods. Different agroclimatic locations as well as factors such as temperature, moisture, and harvesting period may determine the antioxidant content [59]. Assessment of the overall dietary antioxidant capacity rather than individual antioxidant intake has emerged as an alternative approach in the last few years. Similar to the food synergy concept [60], the food antioxidant matrix may be greater than the corresponding action of the individual antioxidants. In other words, the cumulative effects of individual antioxidants may be too small to see a clear effect, and correlations and interactions between the endogenous enzymatic and exogenous non-enzymatic compounds may not be accounted for. In this context, several alternatives have emerged in the last years to measure the oxidative balance of an individual. Yet, there are no unified methodological criteria for the definition of overall antioxidant capacity [61]. A specific oxidative balance index for BC, which accounts for dietary and BC risk factors as well as bioavailability may be useful for further research to clarify the role of antioxidant vitamins and minerals in BC.

The strengths of this study include its prospective and dynamic design, high overall retention (91%), long follow-up, use of reliable measures to collect dietary habits and other lifestyle information, the ability to adjust for multiple potential confounders, and the complete verification of BC cases by a trained oncologist. However, we acknowledge some limitations of the present study. First, dietary information of vitamins and minerals were assessed with a semi-quantitative FFQ, which may be prone to recall bias; nevertheless, the questionnaire has been repeatedly validated [23–25], and we excluded participants with energy intakes outside predefined limits [22]. Second, participants’ diet was evaluated at baseline and may not reflect long-term intake as accurate as repeated measurements of diet during follow-up. Third, we did not take into consideration antioxidant capacity losses caused by cooking methods. Fourth, absence of residual confounding cannot be assumed; however, we adjusted for several potential BC risk factors based on prior literature and previous findings of the SUN cohort. Fifth, the relatively small numbers of BC cases in our cohort may have somewhat limited the statistical power to examine associations. Additionally, multiple testing might explain the presence of significant results in our study, as we examined several compounds; nevertheless, most of the results remained non-significant. Therefore, replication of our findings in larger cohorts should be warranted. Lastly, the participants’ characteristics and homogeneity (Mediterranean middle-age with graduate education) may not represent the general population. In turn, the generalization of our findings should be based on biological mechanisms rather than on statistical representativeness. Moreover, the homogeneity of our cohort increases the reliability of the self-reported data collection and reduces confusion related to education and other socioeconomic factors, increasing the internal validity of these results.
5. Conclusions
We found no evidence for a consistent association between intake of vitamins A, C, and E, selenium, and zinc and BC risk either in overall or premenopausal women in this prospective study of the SUN cohort. For postmenopausal women, we observed an inverse association between antioxidant intake and BC risk for vitamin E, but not for the rest of the antioxidants. Our results are in line with most of the findings of cohort studies. Our results, however, should be interpreted with caution, and replication of our findings in larger cohorts should be warranted. Further investigations should consider overall antioxidant capacity concerning BC incidence.

Supplementary Materials: The following are available online at https://www.mdpi.com/2076-3921/10/3/340/s1, Table S1: Sources of variability (cumulative R^2) and main sources (%) of dietary vitamin A, vitamin C, vitamin E, selenium, and zinc intake according to each food included in the FFQ and food groups. Table S2: Sensitivity analyses: luminal breast cancer. Hazard Ratio (HR) and 95% Confidence Interval (CI) of breast cancer by tertiles of energy-adjusted dietary vitamins A, C, and E, selenium, and zinc at baseline among female participants of the SUN cohort (n = 9983). Table S3: Sensitivity analyses: excluding participants with a follow-up <2 years. Hazard Ratio (HR) and 95% Confidence Interval (CI) for overall, premenopausal, and postmenopausal breast cancer excluding participants with short period of follow-up (<2 years after entering into the cohort). Table S4: Sensitivity analyses: truncating participants’ follow-up at 10 years. Hazard Ratio (HR) and 95% Confidence Interval (CI) for overall, premenopausal, and postmenopausal breast cancer truncating follow-up after 10 years. Supplemental Table S5: Sensitivity analyses: total (dietary + supplements) intake of vitamins A, C, and E, and zinc. Hazard Ratio (HR) and 95% Confidence Interval (CI) of breast cancer by tertiles of energy-adjusted of total (dietary + supplements) intake of vitamins A, C, and E, and zinc at baseline among female participants of the SUN cohort.

Author Contributions: Conceptualization, C.I.F.-L., M.Á.M.-G. and E.T.; methodology, C.I.F.-L., M.Á.M.-G. and E.T.; formal Analysis, C.I.F.-L. and E.T.; interpretation of data, C.I.F.-L., M.Á.M.-G., I.A.-B., A.G., A.R.-N., M.R.-C. and E.T.; writing—original data, C.I.F.-L. and A.R.-N.; writing—review and editing, M.Á.M.-G., I.A.-B., A.G., A.R.-N., M.R.-C. and E.T. All authors have read and agreed to the published version of the manuscript.

Funding: The SUN Project has received funding from the Spanish Government-Instituto de Salud Carlos III, and the European Regional Development Fund (FEDER) (RD 06/0045, CIBER-OBN, Grants PI10/02658, PI10/02293, PI13/00615, PI14/01668, PI14/01798, PI14/01764, PI17/01795, and G03/140), the Navarra Regional Government (27/2011, 45/2011, 122/2014), and the University of Navarra.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of University of Navarra (protocol code 010830).

Informed Consent Statement: All participants were duly informed of their right to refuse to participate in the SUN Study or withdraw their consent to participate at any time without punishment, according to the principles of the Declaration of Helsinki. Furthermore, participants received written information on their specific data to be requested by future questionnaires, the protection to safeguard their privacy, and future feedback from the research team. The voluntary completion of the baseline questionnaire was considered to imply informed consent. The Research Ethics Committee of the University of Navarra approved this method to request the informed consent of participants. The questionnaires are available at the study website.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: We thank very specially all participants in the SUN cohort for their long-standing and enthusiastic collaboration and our advisors from Harvard TH Chan School of Public Health Walter Willett, Alberto Ascherio, Frank B. Hu and Meir J. Stampfer who helped us to design the SUN Project, the PREDIMED study and the PREDIMED-PLUS ongoing trial. We thank other members of the SUN Group: Alonso A, Álvarez-Álvarez I, Balaguer A, Barberia-Latas M, Barrio-López MT, Basterra-Gortari FJ, Battezzati A, Bazal P, Be-nito S, Bertoli S, Bes-Rastrollo M, Beunza JJ, Buil-Cosiales
P, Carlos S, de Irala J, de la Fuente-Arrillaga C, de la O V, de la Rosa PA, Delgado-Rodriguez M, Díaz-Gutiérrez J, Diez Espino J, Domínguez L, Donat-Vargas C, Donazar M, Eguaras S, Fernández-Montero A, Fresán U, Galbete C, García-Arellano A, Gardeazábal I, Gutiérrez-Bedmar M, Gomes-Domingos AL, Gómez-Donoso C, Gómez-Gracia E, Góiri E, Góiri L, Guillén F, Hernández-Hernández A, Hershey MS, Hidalgo-Santamaria M, Hu E, Lahortiga F, Leone A, Llaverio M, Llorca J, López del Burgo C, Mari A, Martín A, Martin-Calvo N, Martin-Moreno JM, Martínez JA, Mendonça R, Menéndez C, Molendijk M, Molero P, Muñoz M, Pano O, Pérez de Ciriza P, Pérez-Cornago A, Pérez de Rojas J, Pimenta AM, Ramallal R, Razquin C, Rico-Campà A, Ruiz L, San Julián B, Sánchez D, Sánchez-Bayona R, Sánchez-Tainta A, Sánchez-Villegas A, Santiago S, Sayón-Orea C, Vázquez Z, Zazpe I.

Conflicts of Interest: The sponsors had no role in the design, execution, interpretation, or writing of the study.

References

1. Wild, C.P.; Weiderpass, E.; Stewart, B.W. (Eds.) World Cancer Report: Cancer Research for Cancer Prevention; International Agency for Research on Cancer: Lyon, France, 2020. Available online: http://publications.iarc.fr/586 (accessed on 22 December 2020).

2. Naghavi, M.; Abajobir, A.A.; Abbafati, C.; Abbas, K.M.; Abd-Allah, F.; Abera, S.F.; Aboyans, V.; Adetokunboh, O.; Ärnlöv, J.; Afshin, A.; et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1151–1210. [CrossRef]

3. Smittenaar, C.R.; Petersen, K.A.; Stewart, K.; Moitt, N. Cancer incidence and mortality projections in the UK until 2035. Br. J. Cancer 2016, 115, 1147–1155. [CrossRef] [PubMed]

4. National Institute of Statistics. Deaths According to Cause of Death. 2018. Available online: https://www.ine.es/en/prensa/edcm_2018_en.pdf (accessed on 30 November 2020).

5. Anand, P.; Kunnumakara, A.B.; Sundaram, C.; Harikumar, K.B.; Tharakan, S.T.; Lai, O.S.; Sung, B.; Aggarwal, B.B. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 2008, 25, 2097–2116. [CrossRef]

6. Vera-Ramírez, L.; Sanchez-Rovira, P.; Abbas, K.M.; Abd-Allah, F.; Abera, S.F.; Aboyans, V.; Adetokunboh, O.; Ärnlöv, J.; Afshin, A.; et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1151–1210. [CrossRef]

7. Xu, L.; Peterson, L.L. The impact of diet on breast cancer outcomes. Curr. Nutr. Rep. 2019, 8, 212–221. [CrossRef] [PubMed]

8. Brown, K.F.; Rumgay, H.; Dunlop, C.; Ryan, M.; Quartly, F.; Cox, A.; Deas, A.; Elliss-Brookes, L.; Gavin, A.; Hounsome, L.; et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br. J. Cancer 2018, 118, 1130–1141. [CrossRef]

9. Key, T.J.; Bradbury, K.E.; Perez-Cornago, A.; Sinha, R.; Tsilidis, K.K.; Tsugane, S. Diet, nutrition, and cancer risk: What do we know and what is the way forward? BMJ 2020, 368, m511. [CrossRef] [PubMed]

10. Kapil, U.; Bhadoria, A.S.; Sareen, N.; Singh, P.; Dwivedi, S.N. Role of Micronutrients in Breast Cancer: A Review. Int. J. Basic Appl. Med. Sci. 2013, 3, 190–200.

11. Chen, Q.; Espey, M.G.; Sun, A.Y.; Pooput, C.; Kirk, K.L.; Krishna, M.C.; Khosh, D.B.; Drisko, J.; Levine, M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl. Acad. Sci. USA 2008, 105, 11105–11109. [CrossRef]

12. Kang, D.H. Oxidative stress, DNA damage, and breast cancer. AACN Clin. Issues 2002, 13, 540–549. [CrossRef] [PubMed]

13. Moloney, J.N.; Cotter, T.G. ROS signalling in the biology of cancer. Semin. Cell Dev. Biol. 2018, 80, 50–64. [CrossRef] [PubMed]

14. George, S.; Abrahamse, H. Redox potential of antioxidants in cancer progression and prevention. Antioxidants 2020, 9, 1156. [CrossRef] [PubMed]

15. Michels, K.B.; Mohillaje, A.P.; Roset-Bahmanyar, E.; Beehler, G.P.; Moysich, K.B. Diet and breast cancer: A review of the prospective observational studies. Cancer 2007, 109, 2712–2749. [CrossRef]

16. Fulan, H.; Changxing, J.; Yi Baina, W.; Wencui, Z.; Chunqing, L.; Fan, W.; Dandan, L.; Dianjun, S.; Tong, W.; Da, P.; et al. Retinol, vitamins A, C, and e and breast cancer risk: A meta-analysis and meta-regression. Cancer Causes Control 2011, 22, 1383–1396. [CrossRef]

17. Zeng, J.; Gu, Y.; Fu, H.; Liu, C.; Zou, Y.; Chang, H. Association between one-carbon metabolism-related vitamins and risk of breast cancer: A systematic review and meta-analysis of prospective studies. Clin. Breast Cancer 2020, 20, e469–e480. [CrossRef]

18. Kuria, A.; Fang, X.; Li, M.; Han, H.; He, J.; Aaseth, J.O.; Cao, Y. Does dietary intake of selenium protect against cancer? A systematic review and meta-analysis of population-based prospective studies. Crit. Rev. Food Sci. Nutr. 2020, 60, 684–694. [CrossRef]

19. Zhang, D.; Xu, P.; Li, Y.; Wei, B.; Yang, S.; Zheng, Y.; Lyu, L.; Deng, Y.; Zhai, Z.; Li, N.; et al. Association of vitamin C intake with breast cancer risk and mortality: A meta-analysis of observational studies. Aging 2020, 12, 18415–18435. [CrossRef] [PubMed]

20. SUN Project Coordinators. The SUN Project [Proyecto SUN]. Available online: www.proyectosun.es (accessed on 23 February 2021).

21. Carlos, S.; De La Fuente-Arrillaga, C.; Bes-Rastrollo, M.; Razquin, C.; Rico-Campà, A.; Martínez-González, M.A.; Ruiz-Canela, M. Mediterranean diet and health outcomes in the SUN cohort. Nutrients 2018, 10, 439. [CrossRef] [PubMed]
22. Willett, W. *Nutritional Epidemiology*, 3rd ed.; Oxford University Press: New York, NY, USA, 2013.

23. de la Fuente-Arrillaga, C.; Vázquez Ruiz, Z.; Bes-Rastrollo, M.; Sampson, L.; Martínez-González, M.A. Reproducibility of an FFQ validated in Spain. *Public Health Nutr.* 2010, 13, 1364–1372. [CrossRef]

24. Martín-Moreno, J.M.; Boyle, P.; Gorgojo, L.; Maisonneuve, P.; Fernandez-Rodriguez, J.C.; Salvini, S.; Willet, W. Development and validation of a food frequency questionnaire in Spain. *Int. J. Epidemiol.* 1993, 22, 512e9. [CrossRef]

25. Fernández-Ballart, J.D.; Piñol, J.L.; Zazpe, I.; Corella, D.; Carrasco, P.; Toledo, E.; Perez-Bauers, M.; Martínez-González, M.A.; Salas-Salvadó, J.; Martín-Moreno, J.M.; et al. Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. *Br. J. Nutr.* 2010, 103, 1808–1816. [CrossRef]

26. Moreiras, O.; Carballo, A.; Cabrera, L.; Cuadrado, C. *Tablas de Composicion de Alimentos (Food Composition Tables)*, 15th ed.; Piraímdre: Madrid, Spain, 2011.

27. Mataix-Verdú, J.; García-Díaz, L.; Manas, M.; Martínez-Victoria, E.; Sanchez, J.; Borregón, A. *Tabla de Composicion de Alimentos*(Spanish Food Composition Tables), 4th ed.; Universidad de Granada Press: Granada, Spain, 2003.

28. Bes-Rastrollo, M.; Valdivieso-Pérez, J.; Sánchez-Villegas, A.; Alonso, A.; Martínez-González, M.A. Validación del peso e índice de masa corporal auto-declarados de los participantes de una cohorte de graduados universitarios [validation of self-reported weight and body mass index of participants from a cohort of college graduates]. *Rev. Esp. Obes.* 2005, 3, 352–358.

29. Martínez-González, M.A.; López-Fontana, C.; Varo, J.J.; Sánchez-Villegas, A.; Martínez, J.A. Validation of the Spanish version of the physical activity questionnaire used in the Nurses’ Health Study and the Health Professionals’ Follow-up Study. *Public Health Nutr.* 2005, 8, 920–927. [CrossRef] [PubMed]

30. Trichopoulou, A.; Costacou, T.; Bamia, C.; Trichopoulou, D. Adherence to a Mediterranean diet and survival in a greek population. *N. Engl. J. Med.* 2003, 348, 2599–2608. [CrossRef]

31. Sánchez-Quesada, C.; Romanos-Nanclares, A.; Navarro, A.M.; Gea, A.; Cervantes, S.; Martínez-González, M.A.; Toledo, E. Coffee consumption and breast cancer risk in the SUN project. *Eur. J. Nutr.* 2020, 59, 3461–3471. [CrossRef] [PubMed]

32. Romanos-Nanclares, A.; Toledo, E.; Gardeazabal, I.; Jiménez-Moleón, J.J.; Martínez-González, M.A.; Gea, A. Sugar-sweetened beverage consumption and incidence of breast cancer: The Seguimiento Universidad de Navarra (SUN) Project. *Eur. J. Nutr.* 2019, 58, 2875–2886. [CrossRef]

33. Romanos-Nanclares, A.; Gea, A.; Martínez-González, M.A.; Zazpe, I.; Gardeazabal, I.; Fernandez-Lazaro, C.I.; Toledo, E. Carbohydrate quality index and breast cancer risk in a Mediterranean cohort: The SUN project. *Clin. Nutr.* 2020, 40, 137–145. [CrossRef] [PubMed]

34. Romanos-Nanclares, A.; Sánchez-Quesada, C.; Gardeazabal, I.; Martínez-González, M.A.; Gea, A.; Toledo, E. phenolic acid subclasses, individual compounds, and breast cancer risk in a Mediterranean cohort: The SUN Project. *J. Acad. Nutr. Diet.* 2020, 120, 1002–1015.e5. [CrossRef] [PubMed]

35. Shivappa, N.; Sandin, S.; Löf, M.; Hébert, J.R.; Adami, H.O.; Weiderpass, E. Prospective study of dietary inflammatory index and risk of breast cancer in Swedish women. *Br. J. Cancer* 2015, 113, 1099–1103. [CrossRef]

36. Temple, N.J.; Gladwin, K.K. Fruit, vegetables, and the prevention of cancer: Research challenges. *Nutrition* 2003, 19, 467–470. [CrossRef]

37. Hernán, M.A.; Hernández-Díaz, S.; Robins, J.M. A structural approach to selection bias. *Epidemiology* 2004, 15, 615–625. [CrossRef] [PubMed]

38. Cadeau, C.; Fournier, A.; Mesrine, S.; Clavel-Chapelon, F.; Fagherazzi, G.; Boutron-Ruault, M.C. Vitamin C supplement intake and postmenopausal breast cancer risk: Interaction with dietary vitamin C. *Am. J. Clin. Nutr.* 2016, 104, 228–234. [CrossRef]

39. Dorigochoo, T.; Shrubsole, M.J.; Shu, X.O.; Lu, W.; Ruan, Z.; Zheng, Y.; Cai, H.; Dai, Q.; Gu, K.; Gao, Y.T.; et al. Vitamin supplement use and risk for breast cancer: The Shanghai breast cancer study. *Breast Cancer Res. Treat.* 2008, 111, 269–278. [CrossRef]

40. Nagel, G.; Linseisen, J.; Van Gils, C.H.; Peeters, P.H.; Boutron-Ruault, M.C.; Clavel-Chapelon, F.; Romieu, I.; Tjønneland, A.; Olsen, A.; Roswall, N.; et al. Dietary β-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Breast Cancer Res. Treat.* 2010, 119, 753–765. [CrossRef]

41. Michels, K.B.; Holmberg, L.; Bergkvist, L.; Jheng, H.; Bruce, K.; Wolk, A. Dietary antioxidant vitamins, retinol, and breast cancer incidence in a cohort of Swedish women. *Int. J. Cancer* 2001, 91, 563–567. [CrossRef]

42. Pantavos, A.; Ruiter, R.; Feskens, E.F.; De Keyser, C.E.; Hofman, A.; Stricker, B.H.; Franco, O.H.; Kieft-De Jong, J.C. Total dietary antioxidant capacity, individual antioxidant intake and breast cancer risk: The Rotterdam study. *Int. J. Cancer* 2015, 136, 2178–2186. [CrossRef]

43. Pan, S.Y.; Zhou, J.; Gibbons, L.; Morrison, H.; Wen, S.W. Antioxidants and breast cancer risk- a population-based case-control study in Canada. *BMJ Cancer* 2011, 11, 1–12. [CrossRef]

44. Spanish Federation of Nutrition, Food and Dietetic Associations (FESNAD). Ingesta dietética de referencia (IDR) para la población española [recommended dietary allowances for Spanish population]. *Acta Diét.* 2010, 14, 196–197.

45. Olza, J.; Aranceta-Bartrina, J.; González-Gross, M.; Ortega, R.; Serra-Majem, L.; Varela-Moreiras, G.; Gil, A. Reported dietary intake and food sources of zinc, selenium, and vitamins a, e and c in the spanish population: Findings from the ANIBES study. *Nutrients* 2017, 9, 697. [CrossRef]

46. Baratta, M.; Miretti, S.; Macchi, E.; Accornero, P.; Martignani, E. Mammary stem cells in domestic animals: The role of ROS. *Antioxidants* 2018, 7, 6. [CrossRef] [PubMed]

47. Nimse, S.B.; Pal, D. Free radicals, natural antioxidants, and their reaction mechanisms. *RSC Adv.* 2015, 5, 27986–28006. [CrossRef]
48. Altucci, L.; Gronemeyer, H. The promise of retinoids to fight against cancer. *Nat. Rev. Cancer* **2001**, *1*, 181–193. [CrossRef] [PubMed]

49. Ho, E. Zinc deficiency, DNA damage and cancer risk. *J. Nutr. Biochem.* **2004**, *15*, 572–578. [CrossRef]

50. Jackson, M.I.; Combs, G.F. Selenium and anticarcinogenesis: Underlying mechanisms. *Curr. Opin. Clin. Nutr. Metab. Care* **2008**, *11*, 718–726. [CrossRef] [PubMed]

51. Ullah, M.F.; Khan, H.Y.; Zubair, H.; Shamim, U.; Hadi, S.M. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: Implications for chemotherapeutic action against cancer. *Cancer Chemother. Pharmacol.* **2011**, *67*, 103–110. [CrossRef]

52. Aggarwal, B.B.; Sundaram, C.; Prasad, S.; Kannappan, R. Tocotrienols, the vitamin E of the 21st century: Its potential against cancer and other chronic diseases. *Biochem. Pharmacol.* **2010**, *80*, 1613–1631. [CrossRef]

53. Yang, C.S.; Luo, P.; Zeng, Z.; Wang, H.; Malafa, M.; Suh, N. Vitamin E and cancer prevention: Studies with different forms of tocopherols and tocotrienols. *Mol. Carcinog.* **2020**, *59*, 365–389. [CrossRef] [PubMed]

54. Miquel, J.; Ramírez-Bosca, A.; Ramírez-Bosca, J.V.; Alperi, J.D. Menopause: A review on the role of oxygen stress and favorable effects of dietary antioxidants. *Arch. Gerontol. Geriatr.* **2006**, *42*, 289–306. [CrossRef]

55. Wang, Z.; Chandrasena, E.R.; Yuan, Y.; Peng, K.W.; Van Breemen, R.B.; Thatcher, G.R.J.; Bolton, J.L. Redox cycling of catechol estrogens generating apurinic/apyrimidinic sites and 8-oxo-deoxyguanosine via reactive oxygen species differentiates equine and human estrogens. *Chem. Res. Toxicol.* **2010**, *23*, 1365–1373. [CrossRef]

56. Agarwal, A.; Doshi, S. The role of oxidative stress in menopause. *J. Midlife Health* **2013**, *4*, 140. [CrossRef]

57. Cilla, A.; Bosch, L.; Barberá, R.; Alegria, A. Effect of processing on the bioaccessibility of bioactive compounds—A review focusing on carotenoids, minerals, ascorbic acid, tocopherols and polyphenols. *J. Food Compos. Anal.* **2018**, *68*, 3–15. [CrossRef]

58. Guillén, S.; Mir-Bel, J.; Oria, R.; Salvador, M.L. Influence of cooking conditions on organoleptic and health-related properties of artichokes, green beans, broccoli and carrots. *Food Chem.* **2017**, *217*, 209–216. [CrossRef]

59. Kalt, W. Effects of production and processing factors on major fruit and vegetable antioxidants. *J. Food Sci.* **2005**, *70*, R11–R19. [CrossRef]

60. Hu, F.B. Dietary pattern analysis: A new direction in nutritional epidemiology. *Curr. Opin. Lipidol.* **2002**, *13*, 3–9. [CrossRef] [PubMed]

61. Hernández-Ruiz, Á.; García-Villanova, B.; Guerra-Hernández, E.; Amiano, P.; Ruiz-Canela, M.; Molina-Montes, E. A review of a priori defined oxidative balance scores relative to their components and impact on health outcomes. *Nutrients* **2019**, *11*, 774. [CrossRef] [PubMed]